Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitis
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Fatty liver
- Focus Therapeutic Use
- 29 Jun 2017 Status changed from recruiting to completed.
- 07 Oct 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 02 Sep 2015 New trial record